Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

NCT04006210 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

COMBINATION_PRODUCT: ND0612 Solution for SC infusion
COMBINATION_PRODUCT: Placebo for SC infusion
DRUG: Oral IR-LD/CD
DRUG: Placebo for Oral IR-LD/CD

Sponsor

NeuroDerm Ltd.